Comprehensive Genomic Profilings in Solid Tumor Patients before Completion of Standard Therapy(NCCH2409 FORESIGHT)

A Feasibility Study on Real-World Timings and Logics of Comprehensive Genomic Profilings in Solid Tumor Patients before Completion of Standard Therapy(NCCH2409 FORESIGHT) - FORESIGHT study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032250660

Enrollment

600

Registered

2026-01-21

Start date

2026-01-29

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor comprehensive genomic profiling

Interventions

CGP testing using tumor tissue and or peripheral blood samples is performed in patients with solid tumors before completion of standard therapy including those expected to complete standard therapy, a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients who have already participated in this study and have previously undergone CGP testing under the framework of Advanced Medical Care A.

Design outcomes

Primary

Measure	Time frame
The proportion of patients who receive molecularly targeted therapy corresponding to actionable genomic alterations identified by the CGP testing performed in this study, including standard-of-care treatments prescribed based on approved companion diagnostics.	—

Secondary

Measure	Time frame
-The proportion of patients for whom molecularly targeted therapy is recommended based on actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients enrolled in clinical trials evaluating molecularly targeted therapies corresponding to actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients in whom diagnostically informative genomic alterations are identified by the CGP test performed in this study. -Overall survival	—

Measure

Time frame

-The proportion of patients for whom molecularly targeted therapy is recommended based on actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients enrolled in clinical trials evaluating molecularly targeted therapies corresponding to actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients in whom diagnostically informative genomic alterations are identified by the CGP test performed in this study. -Overall survival

—

Contacts

Public ContactHiroyuki Fujii

National Cancer Center Hospital Japan

hifuj2@ncc.go.jp+81-3-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026